CN106390102A - 一种治疗精神分裂症的西药组合物 - Google Patents
一种治疗精神分裂症的西药组合物 Download PDFInfo
- Publication number
- CN106390102A CN106390102A CN201611081972.3A CN201611081972A CN106390102A CN 106390102 A CN106390102 A CN 106390102A CN 201611081972 A CN201611081972 A CN 201611081972A CN 106390102 A CN106390102 A CN 106390102A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- gains
- schizoid
- medicine compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 201000000980 schizophrenia Diseases 0.000 title abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 19
- 239000011720 vitamin B Substances 0.000 claims abstract description 19
- RXKMOPXNWTYEHI-RDRKJGRWSA-N Flunarizine hydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 RXKMOPXNWTYEHI-RDRKJGRWSA-N 0.000 claims abstract description 18
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims abstract description 18
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims abstract description 18
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 18
- 229960002807 flunarizine hydrochloride Drugs 0.000 claims abstract description 18
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960001534 risperidone Drugs 0.000 claims abstract description 18
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 claims abstract description 17
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims abstract description 17
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims abstract description 17
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960002252 carbenoxolone sodium Drugs 0.000 claims abstract description 17
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims abstract description 17
- 229960003324 clavulanic acid Drugs 0.000 claims abstract description 17
- 229960000762 perphenazine Drugs 0.000 claims abstract description 17
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 17
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000012153 distilled water Substances 0.000 claims abstract description 16
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 claims abstract description 15
- 229950002441 glucurolactone Drugs 0.000 claims abstract description 15
- 238000003756 stirring Methods 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 32
- NDYMQXYDSVBNLL-UHFFFAOYSA-N (9beta,10alpha,16alpha,23E)-25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)C=CC(C)(C)OC(=O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C NDYMQXYDSVBNLL-UHFFFAOYSA-N 0.000 claims description 17
- VVBWBGOEAVGFTN-SYJGCRHZSA-N Cucurbitacin P Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)CCC(C)(O)C)C=C2[C@H]1C[C@@H](O)[C@@H](O)C2(C)C VVBWBGOEAVGFTN-SYJGCRHZSA-N 0.000 claims description 17
- VVBWBGOEAVGFTN-UHFFFAOYSA-N dihydrocucurbitacin F Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2CC(O)C(O)C1(C)C VVBWBGOEAVGFTN-UHFFFAOYSA-N 0.000 claims description 17
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 16
- 229960000698 nateglinide Drugs 0.000 claims description 16
- 210000002826 placenta Anatomy 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 229960000326 flunarizine Drugs 0.000 claims 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 239000002281 placental hormone Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 230000000698 schizophrenic effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Chemical group 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028916 Neologism Diseases 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 101150098694 PDE5A gene Chemical group 0.000 description 1
- -1 aldehyde lactone Chemical class 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000004037 social stress Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗精神分裂症的西药组合物,包括以下重量份数的原料:胎盘素0.5‑2份,羧甲基纤维素钠2‑5份,克拉维酸1‑8份,磷酸二酯酶1‑5份,那格列奈2‑5份,盐酸氟桂利嗪口服液2‑8份,葡醛内酯片2‑5份,甘珀酸钠2‑5份,瓜蒂素2‑5份,利培酮0.5‑2份,奋乃静0.5‑1份,维生素B 0.5‑1份,蒸馏水50‑100份。该西药组合物通过原料复配发挥协同作用,具有疗效好、治疗周期短、毒副作用小、无并发症产生的优点,且制备方法简单,生产成本低,可以有效增强人体免疫力,是一种有效治疗精神分裂症的药物;且口感好,有利于患者长期坚持服用。
Description
技术领域
本发明涉及一种西药组合物,具体是一种治疗精神分裂症的西药组合物。
背景技术
精神分裂症是一组严重损害患者身心健康的精神疾病,现代抗精神病药物尤其是经典型药物毒副反应较重,常常因此而导致维持治疗的失败。我国目前有近600万人罹患精神分裂症。现代医学认为精神分裂症是个非常复杂的疾病,是由多种病因交织在一起,突破了机体的防御能力而发病。迄今为止,本病的发病机制尚不完全清楚。精神分裂症属于中医“癫狂”的范畴,癫证以沉默痴呆、语无伦次、静而多郁为特征;狂证以喧扰不宁、躁妄打骂、动而多怒为特征。因二者在症状上不能截然分开,又能相互转化,故癫狂并称。
精神分裂症发病病因和机理尚未明了,本病的预防主要是早期发现、早期治疗、预防复发和防止发展精神残疾。不良的社会应激因素可以诱发本病发病和复发,应注意学会调整自己的心态,提高适应能力。抗精神病药维持治疗,对防止复发和再住院起着非常重要的作用,应定期复查,坚持服用精神病药物维持治疗。注意社会功能锻炼,防止功能衰退和精神残疾。由于精神分裂症治疗是长期的治疗,患者和家属需要掌握疾病的自我管理技能,尽可能长期维持病情稳定。
近年来,随着人们对精神分裂症的重视,市场上也出现了多种治疗精神分裂症的药品。但是,现有的治疗精神分裂症的药品主要是西药和中药,中药具有疗效长、治疗效果差、口感差的缺点,人们很难坚持;而西药存在毒副作用大,容易出现并发症的缺点。
发明内容
本发明的目的在于提供一种治疗精神分裂症的西药组合物,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种治疗精神分裂症的西药组合物,包括以下重量份数的原料:胎盘素0.5-2份,羧甲基纤维素钠2-5份,克拉维酸1-8份,磷酸二酯酶1-5份,那格列奈2-5份,盐酸氟桂利嗪口服液2-8份,葡醛内酯片2-5份,甘珀酸钠2-5份,瓜蒂素2-5份,利培酮0.5-2份,奋乃静0.5-1份,维生素B 0.5-1份,蒸馏水50-100份。
作为本发明进一步的方案:包括以下重量份数的原料:胎盘素0.8份,羧甲基纤维素钠3份,克拉维酸5份,磷酸二酯酶2份,那格列奈3份,盐酸氟桂利嗪口服液5份,葡醛内酯片3份,甘珀酸钠4份,瓜蒂素3份,利培酮1份,奋乃静0.6份,维生素B 0.7份,蒸馏水80份。
一种治疗精神分裂症的西药组合物的制备方法,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入胎盘素中,搅拌混合均匀;
(3)将步骤(2)所得物在60-75℃温度下烘干;
(4)将克拉维酸、那格列奈、葡醛内酯片和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在0-5℃下搅拌混合5-10min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌10-15min后加入羧甲基纤维素钠,继续搅拌5-10min;
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
作为本发明再进一步的方案:所述步骤(3)将步骤(2)所得物在65℃温度下烘干。
作为本发明再进一步的方案:所述步骤(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在1-3℃下搅拌混合8min。
作为本发明再进一步的方案:所述步骤(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌12min后加入羧甲基纤维素钠,继续搅拌8min。
与现有技术相比,本发明的有益效果是:
该西药组合物通过原料复配发挥协同作用,具有疗效好、治疗周期短、毒副作用小、无并发症产生的优点,且制备方法简单,生产成本低,可以有效增强人体免疫力,是一种有效治疗精神分裂症的药物;且口感好,有利于患者长期坚持服用。
具体实施方式
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
实施例1
一种治疗精神分裂症的西药组合物,包括以下重量份数的原料:胎盘素0.5份,羧甲基纤维素钠2份,克拉维酸1份,磷酸二酯酶1份,那格列奈2份,盐酸氟桂利嗪口服液2份,葡醛内酯片2份,甘珀酸钠2份,瓜蒂素2份,利培酮0.5份,奋乃静0.5份,维生素B 0.5份,蒸馏水50份。
一种治疗精神分裂症的西药组合物的制备方法,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入胎盘素中,搅拌混合均匀;
(3)将步骤(2)所得物在60℃温度下烘干;
(4)将克拉维酸、那格列奈、葡醛内酯片和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在0℃下搅拌混合5min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌10min后加入羧甲基纤维素钠,继续搅拌5min;
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
实施例2
一种治疗精神分裂症的西药组合物,包括以下重量份数的原料:胎盘素2份,羧甲基纤维素钠5份,克拉维酸8份,磷酸二酯酶5份,那格列奈5份,盐酸氟桂利嗪口服液8份,葡醛内酯片5份,甘珀酸钠5份,瓜蒂素5份,利培酮2份,奋乃静1份,维生素B 1份,蒸馏水100份。
一种治疗精神分裂症的西药组合物的制备方法,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入胎盘素中,搅拌混合均匀;
(3)将步骤(2)所得物在75℃温度下烘干;
(4)将克拉维酸、那格列奈、葡醛内酯片和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在5℃下搅拌混合10min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌15min后加入羧甲基纤维素钠,继续搅拌10min;
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
实施例3
一种治疗精神分裂症的西药组合物,包括以下重量份数的原料:胎盘素0.8份,羧甲基纤维素钠3份,克拉维酸5份,磷酸二酯酶2份,那格列奈3份,盐酸氟桂利嗪口服液5份,葡醛内酯片3份,甘珀酸钠4份,瓜蒂素3份,利培酮1份,奋乃静0.6份,维生素B 0.7份,蒸馏水80份。
一种治疗精神分裂症的西药组合物的制备方法,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入胎盘素中,搅拌混合均匀;
(3)将步骤(2)所得物在65℃温度下烘干;
(4)将克拉维酸、那格列奈、葡醛内酯片和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在2℃下搅拌混合8min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌12min后加入羧甲基纤维素钠,继续搅拌8min。
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
对比例1
一种治疗精神分裂症的西药组合物,包括以下重量份数的原料:胎盘素0.8份,羧甲基纤维素钠3份,克拉维酸5份,磷酸二酯酶2份,那格列奈3份,盐酸氟桂利嗪口服液5份,甘珀酸钠4份,瓜蒂素3份,利培酮1份,奋乃静0.6份,维生素B 0.7份,蒸馏水80份。
一种治疗精神分裂症的西药组合物的制备方法,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入胎盘素中,搅拌混合均匀;
(3)将步骤(2)所得物在65℃温度下烘干;
(4)将克拉维酸、那格列奈和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在2℃下搅拌混合8min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌12min后加入羧甲基纤维素钠,继续搅拌8min。
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
对比例2
一种治疗精神分裂症的西药组合物,包括以下重量份数的原料:胎盘素0.8份,羧甲基纤维素钠3份,克拉维酸5份,磷酸二酯酶2份,那格列奈3份,盐酸氟桂利嗪口服液5份,葡醛内酯片3份,甘珀酸钠4份,利培酮1份,奋乃静0.6份,维生素B 0.7份,蒸馏水80份。
一种治疗精神分裂症的西药组合物的制备方法,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入胎盘素中,搅拌混合均匀;
(3)将步骤(2)所得物在65℃温度下烘干;
(4)将克拉维酸、那格列奈、葡醛内酯片和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)磷酸二酯酶和维生素B分别研磨成粉末,并在2℃下搅拌混合8min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌12min后加入羧甲基纤维素钠,继续搅拌8min。
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
采用本发明实施例1-3和对比例1-2制备的西药组合物治疗精神分裂症的试验研究:
作为实验患者的精神分裂症患者,按如下诊断标准确诊:(1)反复出现言语性幻听;2)明显的思维松弛、思维破裂、言语不连贯,或思维内容贫乏;(3)思想被插入、被撤走、被播散、思维中断,或强制性思维;(4)被动、被控制,或被洞悉体验;(5)原发性妄想(包括妄想知觉,妄想心境)或其他荒谬的妄想;(6)思维逻辑倒错、病理性象征性思维,或语词新作;(7)情感倒错,或明显的情感淡漠;(8)紧张综合征、怪异行为,或愚蠢行为;(9)明显的意志减退或缺乏。排除器质性精神障碍,及精神活性物质和非成瘾物质所致精神障碍。
将120例精神分裂症患者,随机分为6组,每组20人,分别实验1组、实验2组、实验3组、实验4组、实验5组和对照组;年龄18-60岁,病程6个月到l0年。6组病例性别、年龄、病程等资料,差异无统计学意义(P>0.05),有可比性。
实验1组每日口服实施例1制备的西药组合物,一次2-3g,一日两次,3个月为一个疗程,治疗一个疗程后出院;实验2组每日口服实施例2制备的西药组合物,一次2-3g,一日两次,3个月为一个疗程,治疗一个疗程后出院;实验3组每日口服实施例3制备的西药组合物,一次2-3g,一日两次,3个月为一个疗程,治疗一个疗程后出院;实验4组每日口服对比例1制备的西药组合物,一次2-3g,一日两次,3个月为一个疗程,治疗一个疗程后出院;实验5组每日口服对比例2制备的西药组合物,一次2-3g,一日两次,3个月为一个疗程,治疗一个疗程后出院;对照组每日口服利培酮,按照说明书服用,治3个月后出院。且6组出院后均坚持继续服用,于出院时、6个月、1年作出3个时段的疗效评价。
疗效标准拟定如下:
显效:服用1个疗程后,症状完全或基本消失,自知力存在;
有效:服用1个疗程后,症状基本消失,部分自知力存在;
无效:服用1个疗程后,症状毫无减轻,自知力未恢复。
6组病例均于入院时和出院时接受《精神症状评定量表》(BPRS)评分;并于6个月和1年跟踪随访,用《治疗时出现的症状量表)(TESS)进行疗效综合评定(参考张明圆《精神科评定量表手册》[M].北京:人民卫生出版社,2003:81-93,151-152,197-201。)6组患者的BPRS总分和TESS疗效评定比较参见表1、表2。
表16组BPRS总分变化比较
组别 | 病例数 | 入院时分值 | 出院时分值 |
实验1组 | 20 | 34.5±2.3 | 18.5±1.5 |
实验2组 | 20 | 33.9±3.1 | 18.3±2.0 |
实验3组 | 20 | 33.6±2.5 | 18.0±1.3 |
实验4组 | 20 | 34.1±3.5 | 17.9±1.0 |
实验5组 | 20 | 35.0±2.8 | 18.2±1.6 |
对照组 | 20 | 33.5±3.6 | 19.8±2.8 |
表26组TESS疗效评定比较
实验1-3组表示实验1组、实验2组和实验3组的平均值。显效、有效单位:例;有效率单位:%。对比例1中未添加葡醛内酯片,对比例2中未添加瓜蒂素。
有表1-2可以看出,实验1-3组的治疗效果显著优于实验4-5组;且实验1-3组的治疗效果优于对照组,是一种有效的治疗精神分裂症的西药组合物。
该西药组合物通过原料复配发挥协同作用,具有疗效好、治疗周期短、毒副作用小、无并发症产生的优点,且制备方法简单,生产成本低,可以有效增强人体免疫力,是一种有效治疗精神分裂症的药物;且口感好,有利于患者长期坚持服用。
上面对本专利的较佳实施方式作了详细说明,但是本专利并不限于上述实施方式,在本领域的普通技术人员所具备的知识范围内,还可以在不脱离本专利宗旨的前提下做出各种变化。
Claims (6)
1.一种治疗精神分裂症的西药组合物,其特征在于,包括以下重量份数的原料:胎盘素0.5-2份,羧甲基纤维素钠2-5份,克拉维酸1-8份,磷酸二酯酶1-5份,那格列奈2-5份,盐酸氟桂利嗪口服液2-8份,葡醛内酯片2-5份,甘珀酸钠2-5份,瓜蒂素2-5份,利培酮0.5-2份,奋乃静0.5-1份,维生素B 0.5-1份,蒸馏水50-100份。
2.根据权利要求1所述的治疗精神分裂症的西药组合物,其特征在于,包括以下重量份数的原料:胎盘素0.8份,羧甲基纤维素钠3份,克拉维酸5份,磷酸二酯酶2份,那格列奈3份,盐酸氟桂利嗪口服液5份,葡醛内酯片3份,甘珀酸钠4份,瓜蒂素3份,利培酮1份,奋乃静0.6份,维生素B 0.7份,蒸馏水80份。
3.一种如权利要求1-2任一所述的治疗精神分裂症的西药组合物的制备方法,其特征在于,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入胎盘素中,搅拌混合均匀;
(3)将步骤(2)所得物在60-75℃温度下烘干;
(4)将克拉维酸、那格列奈、葡醛内酯片和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在0-5℃下搅拌混合5-10min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌10-15min后加入羧甲基纤维素钠,继续搅拌5-10min;
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
4.根据权利要求3所述的治疗精神分裂症的西药组合物的制备方法,其特征在于,所述步骤(3)将步骤(2)所得物在65℃温度下烘干。
5.根据权利要求3所述的治疗精神分裂症的西药组合物的制备方法,其特征在于,所述步骤(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在1-3℃下搅拌混合8min。
6.根据权利要求3所述的治疗精神分裂症的西药组合物的制备方法,其特征在于,所述步骤(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌12min后加入羧甲基纤维素钠,继续搅拌8min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611081972.3A CN106390102A (zh) | 2016-11-30 | 2016-11-30 | 一种治疗精神分裂症的西药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611081972.3A CN106390102A (zh) | 2016-11-30 | 2016-11-30 | 一种治疗精神分裂症的西药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106390102A true CN106390102A (zh) | 2017-02-15 |
Family
ID=58083991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611081972.3A Withdrawn CN106390102A (zh) | 2016-11-30 | 2016-11-30 | 一种治疗精神分裂症的西药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106390102A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108324685A (zh) * | 2018-04-28 | 2018-07-27 | 武汉田田药业有限公司 | 一种盐酸氟桂利嗪口服溶液的生产工艺 |
JP2019182845A (ja) * | 2018-04-02 | 2019-10-24 | 学校法人藤田学園 | キヌレニンアミノトランスフェラーゼ2(kat2)阻害剤 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101612133A (zh) * | 2009-07-16 | 2009-12-30 | 江苏万邦生化医药股份有限公司 | 那格列奈片及其制备方法 |
CN101890004A (zh) * | 2009-05-18 | 2010-11-24 | 北京瑞伊人科技发展有限公司 | 一种阿莫西林/克拉维酸钾缓释制剂组合物及其制备方法 |
CN102049047A (zh) * | 2009-10-31 | 2011-05-11 | 山东新时代药业有限公司 | 一种药物组合物 |
CN103338752A (zh) * | 2011-04-25 | 2013-10-02 | 山东绿叶制药有限公司 | 利培酮缓释微球组合物 |
-
2016
- 2016-11-30 CN CN201611081972.3A patent/CN106390102A/zh not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101890004A (zh) * | 2009-05-18 | 2010-11-24 | 北京瑞伊人科技发展有限公司 | 一种阿莫西林/克拉维酸钾缓释制剂组合物及其制备方法 |
CN101612133A (zh) * | 2009-07-16 | 2009-12-30 | 江苏万邦生化医药股份有限公司 | 那格列奈片及其制备方法 |
CN102049047A (zh) * | 2009-10-31 | 2011-05-11 | 山东新时代药业有限公司 | 一种药物组合物 |
CN103338752A (zh) * | 2011-04-25 | 2013-10-02 | 山东绿叶制药有限公司 | 利培酮缓释微球组合物 |
Non-Patent Citations (1)
Title |
---|
荆凡波等: "精神分裂症的药物治疗概况及进展", 《齐鲁药事》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019182845A (ja) * | 2018-04-02 | 2019-10-24 | 学校法人藤田学園 | キヌレニンアミノトランスフェラーゼ2(kat2)阻害剤 |
CN108324685A (zh) * | 2018-04-28 | 2018-07-27 | 武汉田田药业有限公司 | 一种盐酸氟桂利嗪口服溶液的生产工艺 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11779549B2 (en) | Treatment of Fragile X Syndrome with cannabidiol | |
CN106390102A (zh) | 一种治疗精神分裂症的西药组合物 | |
US20210369643A1 (en) | Treatment of fragile x syndrome and autism spectrum disorder with cannabidiol | |
CN104435100B (zh) | 一种抗抑郁组合物 | |
Dadić-Hero et al. | Allergic reactions-outcome of sertraline and escitalopram treatments | |
CN106581653A (zh) | 一种治疗精神分裂症的药物组合物 | |
CN105456265B (zh) | 一种盐酸非索非那定在制备治疗精神分裂症药物中的应用 | |
Hasnain et al. | Pharmacological management of psychosis in elderly patients with parkinsonism | |
US20240173339A1 (en) | Cannabinoid formulation for management of depression, anxiety and ptsd, and cannabinoid formulation as a sleep aid | |
CN106727932A (zh) | 一种治疗精神分裂症的中西药组合物 | |
CN106727616A (zh) | 一种治疗精神分裂症的药物 | |
CN106727695A (zh) | 一种治疗精神分裂症的药物组合物及其制备方法和应用 | |
US20230059709A1 (en) | Treatment of fragile x syndrome with cannabidiol | |
CN106692250A (zh) | 一种治疗精神分裂症的中西药组合物及其制备方法和应用 | |
CN106581016A (zh) | 一种治疗精神分裂症的药物组合物及其制备方法和应用 | |
US20160184290A1 (en) | Method of treating schizophrenia | |
US20190008850A1 (en) | Method of treating schizophrenia | |
CN107243010A (zh) | 血红素在改善睡眠障碍的药物及保健食品中的应用 | |
CN106361737A (zh) | 曲尼司特在制备治疗结核病的药物中的应用 | |
CN106729652A (zh) | 一种治疗抑郁症的西药组合物及其制备方法 | |
CN109464436A (zh) | 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用 | |
Xie et al. | Suspended moxibustion plus point injection for 56 children with neurogenic frequent micturition | |
Little et al. | Early depressive stupor responsive to moclobemide | |
EP3466414A1 (en) | Use of nootkatone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170215 |